Document is current

Article History

Received: 21 October 2024

Accepted: 12 December 2024

First Online: 18 January 2025

Declarations

:

: This study and manuscript have been promoted by Novo Nordisk Pharma SA. Alberto Martín-Lorenzo is an employee of Novo Nordisk Pharma SA and Volker Schnecke is an employee of Novo Nordisk A/S. Lluís Segú, Max Brosa, Ened Rodríguez-Urgellés and Miquel Sastre-Belío are employees in PharmaLex Spain, which have received a consulting fee from Novo Nordisk Pharma SA. María Dolores Ballesteros-Pomar have recieved honoraria or consultancy services from Novo Nordisk Pharma SA, Lilly, Bohringer, Fresenius Kabi, Nutricia Danone, Nestlé Healthcare, Vegenat and Abbott Nutrition. Nuria Vilarrasa have received honoraria for consultancy services from Novo Nordisk Pharma SA, Lilly, Boeringher-Ingelheim, Adventia Pharma and FAES Pharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

: The results presented in this manuscript are based on published studies. All procedures performed in those studies involving human participants were conducted in accordance with the ethical standards of the local Institutional Review Boards for each site and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in publication of these studies.